GC
AVEO

Grimes & Company’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Grimes & Company’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,380
Closed -$159K – 309
2022
Q3 		$159K Hold
19,380
– – 0.01% 258
2022
Q2 		$127K Hold
19,380
– – 0.01% 265
2022
Q1 		$108K Hold
19,380
– – 0.01% 292
2021
Q4 		$91K Sell
19,380
-2,260
-10% -$14K ﹤0.01% 292
2021
Q3 		$134K Buy
+21,640
New +$129K 0.01% 293
2020
Q1 		– Sell
-2,260
Closed -$14K – 279
2019
Q4 		$14K Hold
2,260
– – ﹤0.01% 265
2019
Q3 		$19K Hold
2,260
– – ﹤0.01% 255
2019
Q2 		$15K Hold
2,260
– – ﹤0.01% 242
2019
Q1 		$19K Hold
2,260
– – ﹤0.01% 241
2018
Q4 		$36K Hold
2,260
– – ﹤0.01% 228
2018
Q3 		$75K Hold
2,260
– – 0.01% 236
2018
Q2 		$51K Hold
2,260
– – ﹤0.01% 231
2018
Q1 		$66K Hold
2,260
– – 0.01% 236
2017
Q4 		$63K Hold
2,260
– – 0.01% 212
2017
Q3 		$82K Buy
+2,260
New +$69.9K 0.01% 197

Other funds holding AVEO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Grimes & Company's AVEO Position: Q4 2022 in Review

Grimes & Company sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 19,380 shares — an estimated $159K sold.

Grimes & Company first reported a position in AVEO in Q3 2017 and held it in 15 quarters. The position peaked at $159K in Q3 2022. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

  • Grimes & Company reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Grimes & Company sold 19,380 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $159K.
  • Grimes & Company first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 15 quarters.
  • Grimes & Company's AVEO Pharmaceuticals, Inc. position peaked at $159K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on Grimes & Company's 13F filing for Q4 2022, filed 25 Jan 2023.